2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

508. Bone Marrow Failure: Acquired: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Bioinformatics, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Immunology, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Pediatric
PAPER

1405 Romiplostim N01 for refractory and relapsed severe aplastic anemia: A single-arm retrospective study

Jinsong JIA, MD, PhD, Pinqi Duan2, Hao Jiang3, Xiaojun Huang, MD,PhD4
1 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Beijing, China
2 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Beijing, China
3 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Beijing, China
4 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Beijing, China
Introduction
For patients with severe aplastic anemia (SAA) who are refractory to or have relapsed after standard immunosuppressive therapy (IST) or cyclosporine A (CsA) combined with an oral thrombopoietin receptor agonist (TPO-RA), effective subsequent treatment options remain limited. Romiplostim N01 for Injection (Romiplostim N01), a long-acting TPO-RA, has demonstrated potential in promoting hematopoietic recovery in multiple clinical trials. However, real-world evidence regarding its use as a salvage therapy in Chinese patients with refractory/relapsed SAA following failure of IST or CsA plus a TPO-RA is still scarce. This single-arm retrospective study aimed to evaluate the clinical efficacy and hematologic response of Romiplostim N01 in this patient population.
Methods
We retrospectively analyzed 34 patients with SAA who were assessed as non-responsive (NR) after 6 months of prior standard IST or CsA combined with an oral TPO-RA. The median age was 52.5 years (range, 15–80), with 15 males and 19 females. All patients received weekly subcutaneous injections of Romiplostim N01, starting at 10 μg/kg, with dose titration up to a maximum of 20 μg/kg based on peripheral platelet counts. Complete blood counts were monitored weekly, hematologic responses were evaluated monthly, and the total follow-up duration was 6 months.
Results
Compared with baseline, all three blood cell lineages—platelets, neutrophils, and hemoglobin—showed significant improvements at each of the six time points (months 1 through 6 [M1–M6]). At 6 months, the mean increases from baseline were 68.6 × 10?/L for platelets, 1.4 × 10?/L for neutrophils, and 25.4 g/L for hemoglobin. The best overall response rate (ORR) was 76.5% (26/34; 95% CI: 58.8%–89.3%), with a complete response (CR) rate of 47.1% (16/34) and a partial response (PR) rate of 29.4% (10/34).
Conclusions
Romiplostim N01 demonstrated durable trilineage hematopoietic recovery in patients with refractory/relapsed SAA. These findings support its use as an effective salvage therapy for this challenging patient population.
Jinsong JIA, MD, PhD: No relevant conflicts of interest to declare.